Combination of UGT1A1 polymorphism and baseline plasma bilirubin levels in predicting the risk of antipsychotic-induced dyslipidemia in schizophrenia patients.

As a kind of strong antioxidant substrates, however, our results indicated that the bilirubin levels in schizophrenia patients still had a decreasing trend during a 4-week AAPD medication even if the psychotic symptoms were alleviated.

also in 47,180 other papers

The TG of the first-episode subgroup, 2–3 subgroups, and ≥4 subgroups showed an increasing trend, and there was a significant difference in the TG between the first-episode subgroup and ≥4 subgroups (TBIL: ANOVA: F (2,238) = 3.266, p = 0.04; First episode vs. >4 episodes: p = 0.041).

also in 63,971 other papers